HomeAbout

TL;DR CNBC


More than 3 million Medicare patients could be eligible for coverage of Wegovy to reduce heart disease risks, study says - TL;DR CNBC

More than 3 million Medicare patients could be eligible for coverage of Wegovy to reduce heart disease risks, study says

Publishing timestamp: 2024-04-24 05:00:01


Summary

More than 3 million people with Medicare could be eligible for coverage of Novo Nordisk's Wegovy, a weight loss drug now approved in the U.S. for heart health. However, some beneficiaries may still face out-of-pocket costs and certain Medicare prescription drug plans may not cover Wegovy until 2025. Medicare's budget could also be strained as more plans cover the costs of Wegovy.


Sentiment: NEUTRAL

Tickers: NOVO.B-DKNVO

Keywords: pharmaceuticalsbusiness newsnovo nordisk a/sbusinessbreaking newsbiotechnologyhealth care industrysocial issuesbiotech and pharmaceuticals

Source: https://www.cnbc.com/2024/04/24/wegovy-3point6-million-medicare-patients-could-get-heart-health-coverage.html


Developed by Leo Phan